MK-677 · Research brief

MK-677 (Ibutamoren): Research Overview, Mechanism & Handling

Real Peptides Research TeamEditorial

Updated September 5, 202610 min read

53 WORDS

Short answer

MK-677 (ibutamoren) is a non-peptide, orally bioavailable growth hormone secretagogue first developed at Merck in the 1990s. Structurally a spiropiperidine, it acts as an agonist at the ghrelin receptor (GHS-R1a). Published research examines pulsatile growth hormone release, IGF-1 signaling, nitrogen balance, body composition, bone and sleep endpoints, and metabolic and hepatic safety markers.

Key takeaways

MK-677 (ibutamoren) is a non-peptide spiropiperidine growth hormone secretagogue that acts as an agonist at the ghrelin receptor (GHS-R1a), not a steroid and not a SARM.
Published work reports stimulation of pulsatile growth hormone release and downstream IGF-1 elevation, with a pharmacokinetic profile described as long relative to injectable secretagogues.
The literature spans rodent somatic growth models, a 1998 clinical study on nitrogen balance during dietary restriction, a 2008 randomized neurology trial that found no clinical effect on Alzheimer's disease progression, and isolated case reports.
Metabolic signals — notably effects on fasting glucose and insulin sensitivity — plus a 2025 case report of hepatotoxicity mean safety evidence remains preliminary and incomplete.
MK-677 is not FDA-approved for any of the applications discussed here and is supplied strictly for laboratory research use only; it is also prohibited in sport as a growth hormone secretagogue.
Supplier evaluation should rest on batch-specific third-party COAs with HPLC purity, mass spectrometry identity confirmation, and traceable lot numbering — not on appearance or price.

What MK-677 Is and Where It Came From

MK-677 emerged from a medicinal chemistry program aimed at replacing injectable growth hormone releasing peptides with an orally active small molecule. Earlier secretagogues such as GHRP-6 and hexarelin demonstrated that a receptor distinct from the GHRH receptor could drive growth hormone release, but their peptide structure limited oral exposure. MK-677 was designed around a benzyl-substituted spiropiperidine scaffold that retains secretagogue activity while surviving gastrointestinal passage, a property that made it attractive for chronic-administration clinical trials.

Two points of classification matter because they are so often confused. First, MK-677 is not an anabolic steroid: it has no steroid nucleus and does not bind the androgen receptor. Second, it is not a SARM, despite being sold alongside compounds like LGD-4033 in gray-market channels. Its molecular target is the ghrelin receptor, which places it in an entirely separate pharmacological family. It is also not a peptide in the strict chemical sense, though it is routinely catalogued with research peptides because it modulates the same somatotropic axis that GHRP and GHRH analogs act on.

Attribute	MK-677 (ibutamoren)
Chemical class	Non-peptide spiropiperidine small molecule
Molecular target	Ghrelin receptor (GHS-R1a)
Pharmacological category	Growth hormone secretagogue
Route studied in published trials	Oral
Regulatory status	Not FDA-approved; research use only
Sport status	Prohibited as a growth hormone secretagogue

Reported Mechanism of Action

The ghrelin receptor is expressed in the anterior pituitary and hypothalamus, with additional distribution in the hippocampus, pancreas, and peripheral tissues. Endogenous ghrelin, secreted largely by the gastric fundus, binds GHS-R1a and drives growth hormone release while also influencing appetite signaling through hypothalamic NPY/AgRP neurons. MK-677 is described in the literature as mimicking this ligand, producing a pattern of secretion that preserves the pulsatile architecture of the growth hormone axis rather than delivering a flat exogenous load.

Downstream of pituitary release, growth hormone acts on hepatic and peripheral tissue to increase insulin-like growth factor 1 (IGF-1), the mediator responsible for much of the anabolic and metabolic signaling attributed to the axis. Published pharmacokinetic work describes a comparatively long plasma residence for MK-677 relative to injectable peptide secretagogues, which is why clinical protocols historically used once-daily oral administration. Two mechanistic features recur across the literature and shape how findings should be interpreted:

Axis-level rather than receptor-bypassing action. Because MK-677 works upstream at the pituitary, negative feedback from somatostatin and IGF-1 remains partially intact — a distinction frequently drawn against exogenous growth hormone administration.
Non-selectivity of ghrelin receptor signaling. The same receptor engagement implicated in growth hormone release is linked to appetite signaling, gastric motility, and glucose regulation, so downstream effects are not confined to the somatotropic axis.

What the Research Literature Examines

The published body of work on MK-677 is narrower than its popularity suggests, and it is unevenly distributed across research areas. The following summary is organized by domain, with the strength of evidence flagged in each case.

Body composition and catabolic states

The best-known clinical investigation, published in The Journal of Clinical Endocrinology and Metabolism in 1998, examined MK-677 in the context of diet-induced catabolism and reported effects on nitrogen balance during caloric restriction. This work established the compound's basic ability to raise growth hormone and IGF-1 with oral administration in humans and is the origin of much subsequent interest. It remains a short-duration study in a controlled setting, and its findings should not be extrapolated to chronic use or to different populations.

Somatic growth in animal models

A 2018 study in the Yonsei Medical Journal evaluated the orally active secretagogue in rats, examining effects on somatic growth. Rodent models remain the primary venue for growth-related questions, and interspecies differences in GHS-R1a expression and growth plate biology mean that findings in animals inform hypotheses rather than settle them.

A randomized trial reported in Neurology in 2008 assessed MK-677 in Alzheimer's disease and found no clinical effect on disease progression, despite the compound's documented activity on the growth hormone/IGF-1 axis. This is one of the more instructive datasets in the literature: it demonstrates that raising a biomarker does not necessarily translate into a clinical outcome, and it tempers speculative claims about neuroprotective or anti-aging applications.

Combined-compound observations

A 2022 case report in Experimental Physiology described concurrent LGD-4033 and MK-677 use in a single individual, with measurements of body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content. As a case report with n=1 and no control condition, it is hypothesis-generating only, and it cannot separate the contributions of the two compounds.

Hepatic and metabolic safety signals

A 2025 case report in BMJ Case Reports described hepatotoxicity associated with MK-677. Single case reports cannot establish causality, but they carry weight in a literature this sparse, particularly where product provenance and purity are unverified. Separately, the metabolic literature has consistently flagged effects on fasting glucose and insulin sensitivity as the mechanistically expected consequence of sustained growth hormone axis stimulation. Evidence on long-term metabolic consequences remains preliminary.

Analytical detection

A 2023 paper in Drug Testing and Analysis reported detection of MK-0677 in equine hair following oral administration — work driven by anti-doping and residue-testing needs. Detection methodology is an active area precisely because the compound is prohibited in competitive sport and appears in unregulated consumer products.

Laboratory Handling: Reconstitution and Storage

MK-677 is typically supplied as a lyophilized powder or as a solid material, and handling practice follows the general conventions applied to small-molecule research compounds rather than those used for fragile peptide chains. In broad terms, laboratories maintain the sealed material in a cool, dry, light-protected environment and allow vials to equilibrate to ambient temperature before opening to limit condensation onto hygroscopic solids.

Reconstitution is performed with an appropriate solvent introduced gently against the vial wall, with swirling rather than vigorous agitation, until the solution is clear and free of particulates. Solutions in aqueous or partly aqueous vehicles are generally refrigerated, protected from light, and treated as having a limited working window; freeze-thaw cycling is minimized because repeated phase transitions are a recognized contributor to degradation across compound classes. Laboratories document reconstitution date, solvent identity, and storage conditions on the vial or in the batch record so that any later analytical anomaly can be traced. Where stability under specific conditions matters to an experimental design, the appropriate answer is a stability-indicating assay on the actual lot, not a general assumption.

Regulatory and Research-Use Status

MK-677 is not approved by the FDA for any of the applications discussed on this page, and it has not completed a development pathway to marketing authorization in any major jurisdiction. It is not a dietary ingredient, and the FDA has publicly cautioned against consumer products marketed with secretagogue and SARM-type ingredients. Material sold by legitimate suppliers, including Real Peptides, is intended for laboratory research use only — in vitro work and controlled preclinical investigation by qualified personnel — and is not for human or veterinary use, food use, or household use.

Separately, MK-677 is prohibited in sport under the growth hormone secretagogue category, which is the practical driver behind detection method development in both human and equine testing contexts. Institutions procuring the compound should confirm that intended use aligns with their own institutional review, chemical hygiene, and record-keeping requirements before acquisition.

How Researchers Evaluate Supplier Quality

Because MK-677 circulates widely in unregulated channels, material identity and purity cannot be assumed. The controls below constitute a reasonable minimum standard for research-grade sourcing, and they are analytical rather than sensory — physical appearance and price are not evidence of anything.

Batch-specific third-party COA. A certificate tied to the exact lot number on the vial, issued by an independent laboratory rather than the seller, and dated within a reasonable window of the production run.
HPLC purity data. A chromatogram, not just a stated percentage, so that impurity peaks and integration can be inspected directly.
Mass spectrometry identity confirmation. Observed mass should match the expected molecular weight of ibutamoren, confirming that the material is what the label claims and not a structurally adjacent substitute.
Batch traceability. Lot numbers that connect the physical vial to its documentation, with retained records on the supplier's side.
Documentation of testing scope. Purity and identity are the baseline; solvent residue and heavy metal screening add value where the research design is sensitive to contaminants.

Where a COA is absent, generic across all products, or unlinked to a specific lot, the prudent assumption is that the material is unverified. Independent re-testing of a received lot is standard practice in well-run laboratories and is the only way to close the loop entirely.

Where the Open Questions Are

Honest reporting on MK-677 means naming what is unresolved, and a great deal is:

Long-term axis adaptation. Whether sustained GHS-R1a agonism produces receptor desensitization, altered pulsatility, or persistent changes after discontinuation is not well characterized in long-duration controlled studies.
Glucose and insulin trajectory. Elevations in fasting glucose and reductions in insulin sensitivity are the mechanistically anticipated consequence of chronic growth hormone elevation, but the magnitude, reversibility, and moderating variables are incompletely mapped.
Hepatic signals. One published case report is a signal, not a dataset. Systematic hepatic monitoring data across a larger population is absent.
Biomarker versus outcome. The 2008 neurology trial is a reminder that IGF-1 elevation does not automatically confer functional benefit, and that endpoint selection determines what a study can actually conclude.
Product provenance in the reported literature. Case reports frequently involve unverified consumer products, which makes it difficult to attribute adverse findings to the molecule itself rather than to contaminants or misidentified material.
Interaction with co-administered compounds. Combination data is essentially limited to isolated case observations, and mechanistic overlap between compound classes has not been systematically studied.

Companion articles across this hub go deeper on individual questions — clearance and detection windows, reconstitution stability, mechanism at the receptor level, comparative pharmacology against SARMs and steroids, and the analytical standards that separate verified material from counterfeit. This page is the map; those articles are the terrain.

Research-grade MK-677 (Ibutamoren): Real Peptides supplies MK-677 (Ibutamoren) for laboratory research with a published third-party Certificate of Analysis for every batch. Research use only.

Explore MK-677 (Ibutamoren) research on Real Peptides

The articles below go deeper on the questions researchers ask most about MK-677 (Ibutamoren).

Research timelines & mechanisms

Safety & side effects

Reconstitution, storage & handling

Research questions

Stacks & comparisons

Legal & regulatory

References

Peer-reviewed sources on MK-677 (Ibutamoren) indexed in PubMed, listed for research context. Real Peptides supplies MK-677 (Ibutamoren) for laboratory research use only.

Hepatotoxicity induced by MK-677. BMJ case reports, 2025. PMID 40675653. doi:10.1136/bcr-2025-265728
LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report. Experimental physiology, 2022. PMID 36303408. doi:10.1113/EP090741
Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats. Yonsei medical journal, 2018. PMID 30450851. doi:10.3349/ymj.2018.59.10.1174
Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology, 2008. PMID 19015485. doi:10.1212/01.wnl.0000335163.88054.e7
MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. The Journal of clinical endocrinology and metabolism, 1998. PMID 9467534. doi:10.1210/jcem.83.2.4551
Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology, 1997. PMID 9349662. doi:10.1159/000127249
Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proceedings of the National Academy of Sciences of the United States of America, 1995. PMID 7624358. doi:10.1073/pnas.92.15.7001

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Neither. MK-677 is a non-peptide spiropiperidine that acts as an agonist at the ghrelin receptor (GHS-R1a), placing it in the growth hormone secretagogue class. It has no steroid nucleus and does not bind the androgen receptor, which is the defining feature of SARMs. The confusion arises because MK-677 is frequently catalogued and sold alongside SARMs in research chemical listings, not because of any shared pharmacology or molecular target.

Published work is limited but real. A 1998 clinical study examined nitrogen balance during dietary restriction, rodent research has looked at somatic growth, and a 2008 randomized trial in Alzheimer's disease found no clinical effect on disease progression despite axis activation. More recent additions include a 2022 case report on combined compound use and a 2025 hepatotoxicity case report. Evidence on long-term outcomes remains preliminary.

MK-677 never completed a development pathway to marketing authorization. It progressed through clinical investigation in the 1990s and 2000s, but trials did not produce the outcome data required for approval — the 2008 Alzheimer's trial is one published example of a negative clinical endpoint. It is not an approved drug, not a dietary ingredient, and is supplied by legitimate vendors for laboratory research use only.

Through analytical documentation rather than inspection. The standard is a batch-specific certificate of analysis from an independent third-party laboratory, containing an HPLC chromatogram demonstrating purity and a mass spectrometry result confirming the observed molecular weight matches ibutamoren. Lot numbers on the vial should trace back to that documentation. Generic certificates unlinked to a specific batch provide no meaningful assurance about the material received.

Two areas recur. Metabolic effects — particularly elevated fasting glucose and reduced insulin sensitivity — are the mechanistically expected consequence of sustained growth hormone axis stimulation and appear consistently in the research discussion. Separately, a 2025 case report in BMJ Case Reports described hepatotoxicity associated with MK-677. Single case reports cannot establish causality, especially where product provenance is unverified, but they warrant attention in a sparse literature.

Because MK-677 is prohibited in sport as a growth hormone secretagogue and appears in unregulated consumer products, testing laboratories need validated detection methods across matrices. A 2023 paper in Drug Testing and Analysis reported detection in equine hair following oral administration, reflecting parallel demand in equine anti-doping and residue testing. Method development in this space also supports forensic and product-surveillance work independent of sport.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA